• Jasplakinolide as an Actin Polymerization Inducer: Mechanism

  2026-05-20

  Jasplakinolide is a potent actin polymerization inducer widely used in cytoskeletal research. Its high-affinity binding to F-actin enables stabilization of actin filaments, supporting advanced studies in cell biology and antifungal research. APExBIO supplies rigorously validated Jasplakinolide (SKU B7189) for reproducible experimental workflows.

• Reliable Signal Amplification with Cy3 TSA Fluorescence Syst

  2026-05-19

  This article addresses common laboratory challenges in detecting low-abundance biomolecules, focusing on the Cy3 TSA Fluorescence System Kit (SKU K1051). Scenario-driven Q&A blocks provide actionable solutions for biomedical researchers, highlighting sensitivity, reproducibility, and compatibility with fluorescence microscopy. The guide draws on peer-reviewed evidence and validated protocols to support confident adoption of this TSA fluorescence kit.

• Topotecan HCl: Protocol Enhancements for Antitumor Research

  2026-05-19

  Topotecan HCl's precise topoisomerase 1 inhibition empowers advanced cancer models and cytotoxicity workflows, particularly for lung and prostate cancer research. This guide details actionable protocol refinements, troubleshooting tips, and practical insights from the latest systems-level studies to maximize antitumor efficacy.

• miR-184's Anti-apoptotic Role in Ovarian Granulosa Cells via

  2026-05-18

  This study uncovers how miR-184, regulated by SREBF2 and H3K4me3, exerts anti-apoptotic effects in ovarian granulosa cells by inducing SMAD3 expression. These findings illuminate a key regulatory axis in follicular atresia, offering new avenues for improving ovarian health and female fertility.

• Ellagic Acid in Precision Senescence Assays: Next-Gen CK2 In

  2026-05-18

  Explore how Ellagic acid enables next-generation, precision senescence and cancer biology research as a selective CK2 inhibitor. This article uniquely integrates molecular selectivity, advanced assay parameters, and AI-driven discovery insights for robust experimental design.

• Topotecan HCl (SKU B2296): Data-Driven Solutions for Cancer

  2026-05-17

  This article guides researchers through common experimental challenges in cell viability and cytotoxicity assays, demonstrating how Topotecan HCl (SKU B2296) enables reproducible, quantitative results. Scenario-based Q&A blocks provide evidence-backed protocols, practical optimization tips, and candid vendor comparisons, all rooted in validated literature and supplier data.

• CX-5461 Induces DNA Damage and Mitotic Catastrophe in Cervic

  2026-05-16

  This study establishes CX-5461, a selective RNA polymerase I inhibitor, as an agent that suppresses cervical cancer cell growth by inducing DNA damage and mitotic catastrophe. The findings highlight its ability to enhance cisplatin sensitivity, suggesting a mechanistically distinct therapeutic strategy for platinum-resistant cervical cancer.

• Pentoxifylline: Translating Mechanism to Therapeutic Innovat

  2026-05-15

  This thought-leadership article explores Pentoxifylline’s multifaceted mechanism as a phosphodiesterase inhibitor, bridging foundational immunology with advanced translational strategies. Integrating mechanistic evidence, protocol guidance, and competitive context, it provides actionable insight for researchers developing next-generation anti-inflammatory and immunomodulatory therapies.

• Cefiderocol Activity Against Resistant European Enterobacter

  2026-05-15

  This study presents the most extensive in vitro assessment to date of cefiderocol's activity against European Enterobacterales, including highly resistant strains. The findings reveal cefiderocol's superior efficacy compared to approved β-lactam/β-lactamase inhibitor combinations, informing therapeutic strategies for carbapenem-resistant infections.

• AM 281: Selective CB1 Cannabinoid Receptor Antagonist for Ne

  2026-05-14

  AM 281 is a potent, selective CB1 cannabinoid receptor antagonist with nanomolar affinity, enabling targeted neuropharmacology research on memory impairment and brain injury. Its efficacy in modulating the CB1-CREB-GLT-1 signaling axis is supported by peer-reviewed studies and validated by APExBIO’s product data. This article details mechanistic insights, protocol guidance, and practical boundaries for AM 281.

• Applied Advances with the γH2AX DNA Damage Detection Kit

  2026-05-14

  Leverage the γH2AX DNA Damage Detection Kit (Mouse mAb/Red) for precise, reproducible quantification of DNA double-strand breaks across cancer, genotoxicity, and apoptosis research. This article details robust workflows, highlights experimental innovations from recent FLASH-RT studies, and delivers troubleshooting strategies to maximize assay sensitivity and reproducibility.

• Targeted Doxycycline Nanoparticles for AAA Therapy: Multifun

  2026-05-13

  The reference study introduces a multifunctional nanomedicine platform using tea polyphenol nanoparticles for precision delivery of doxycycline to abdominal aortic aneurysm (AAA) lesions. This strategy enhances site-specific drug accumulation, improves matrix metalloproteinase inhibition, and reduces systemic toxicity, offering a robust blueprint for next-generation targeted interventions in vascular disease.

• 7-Ethyl-10-hydroxycamptothecin: Redefining Colon Cancer Mode

  2026-05-13

  This thought-leadership article explores how 7-Ethyl-10-hydroxycamptothecin (SN-38) is transforming advanced colon cancer research by bridging mechanistic insight with translational strategy. It unpacks the dual mechanisms—DNA topoisomerase I inhibition and FUBP1 pathway disruption—supported by recent literature, and offers evidence-backed protocol parameters for maximizing assay fidelity. The piece demonstrates how APExBIO’s high-purity compound (SKU N2133) elevates reproducibility and mechanistic depth, guiding translational researchers toward impactful discoveries.

• DNA Damage Pathways Dictate Calicheamicin ADC Response in Le

  2026-05-12

  This study uses genome-wide CRISPR/Cas9 screening to pinpoint DNA damage response genes—particularly TP53, ATM, and MDM2—that modulate the sensitivity of acute leukemia cells to calicheamicin-based antibody–drug conjugates. The findings clarify resistance mechanisms and suggest rational targets for combination strategies to enhance ADC efficacy in acute leukemia.

• MiR-3180 Suppresses HCC Progression by Targeting Lipid Metab

  2026-05-12

  Hong et al. (2023) reveal that miR-3180 inhibits hepatocellular carcinoma (HCC) growth and metastasis by downregulating key regulators of lipid synthesis and uptake, specifically SCD1 and CD36. These findings highlight miR-3180 as a potential therapeutic target and prognostic marker in HCC, offering new directions for metabolic intervention strategies.

16349 records 1/1090 page Next 12345 下5页 Last page